Research Highlights Role of Protein Pair in Obesity Regulation

Feb 12, 2010 by Dama Kimmon
Jorge Moscat, PhD. Image: University of Cincinnati

(PhysOrg.com) -- New research by University of Cincinnati scientists implicates a new protein in obesity development and highlights a protein pair's "team effort" in regulating obesity and insulin resistance.

Jorge Moscat, PhD, chair of UC’s cancer and cell biology department, says that proteins p62 and ERK are involved in adipogeneis, (the development of adipocytes, or ). His new study shows precisely how this duo works together.

The study is published online in advance of print Friday, Feb. 12, 2010, in the journal , and will appear in print in the March 1, 2010, edition.

Earlier research led by Moscat showed that removing or “knocking out” p62 in mice led to the development of obesity and in adulthood. These mice used less energy and created more fat cells than the control group, even with the same diet and activity levels.

Targeting p62 or deficiencies seemed to be a logical next step for potential obesity treatments; however, Moscat says, p62 is not an easy target due to its lack of enzymatic action. In other words, it does not catalyze reactions in a way that would be key for the success of targeted drug therapy. In addition, missing or mutated p62 has also been linked to .

Moscat and his team instead decided to focus their attention on the action of another less-understood protein, ERK, which interacts with p62.

“Thoughts about ERK’s role in obesity have been controversial,” says Moscat. “One theory suggested that it was to restrain production of fat cells. Our study shows a much more devious role for ERK.”

In the new study, Moscat and his team bred mice without p62 and ERK. These “double knockouts” did not develop obesity like the p62 knockouts did, indicating that ERK was the obesity-inducing culprit.

The team’s findings show that p62 works to suppress the action of ERK, so without p62, ERK activity goes uncontrolled.

Moscat says that ERK serves as a better target for obesity therapies because it could be inhibited without affecting p62.

Explore further: Letrozole is a promising new treatment of male infertility, researcher says

Related Stories

'Bridge' protein spurs deadliest stages of breast cancer

Feb 22, 2007

A protein known for its ability to "bridge" interactions between other cellular proteins may spur metastasis in breast cancer, the disease’s deadliest stage, a study from Burnham Institute for Medical Research has found.

Oncoproteins double-team and destroy vital tumor-suppressor

Feb 14, 2008

Two previously unconnected cancer-promoting proteins team up to ambush a critical tumor suppressor by evicting it from the cell's nucleus and then marking it for death by a protein-shredding mechanism, a team led by scientists ...

Recommended for you

Popular antioxidant likely ineffective, study finds

4 hours ago

The popular dietary supplement ubiquinone, also known as Coenzyme Q10, is widely believed to function as an antioxidant, protecting cells against damage from free radicals. But a new study by scientists at McGill University ...

New findings on 'key players' in brain inflammation

4 hours ago

Inflammation is the immune system's natural reaction to an 'aggressor' in the body or an injury, but if the inflammatory response is too strong it becomes harmful. For example, inflammation in the brain occurs ...

Gut microbial mix relates to stages of blood sugar control

Mar 05, 2015

The composition of intestinal bacteria and other micro-organisms—called the gut microbiota—changes over time in unhealthy ways in black men who are prediabetic, a new study finds. The results will be presented Friday ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.